KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Astrana Health (ASTH) over the last 17 years, with Q3 2025 value amounting to $7.4 million.

  • Astrana Health's Free Cash Flow fell 7663.32% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.0 million, marking a year-over-year increase of 3873.71%. This contributed to the annual value of $44.2 million for FY2024, which is 1125.75% up from last year.
  • Per Astrana Health's latest filing, its Free Cash Flow stood at $7.4 million for Q3 2025, which was down 7663.32% from $89.5 million recorded in Q2 2025.
  • Astrana Health's Free Cash Flow's 5-year high stood at $89.5 million during Q2 2025, with a 5-year trough of -$39.1 million in Q3 2022.
  • Moreover, its 5-year median value for Free Cash Flow was $11.3 million (2023), whereas its average is $16.0 million.
  • As far as peak fluctuations go, Astrana Health's Free Cash Flow plummeted by 36678.08% in 2021, and later soared by 66061.5% in 2022.
  • Quarter analysis of 5 years shows Astrana Health's Free Cash Flow stood at -$15.0 million in 2021, then skyrocketed by 660.61% to $84.1 million in 2022, then crashed by 85.43% to $12.2 million in 2023, then crashed by 210.1% to -$13.5 million in 2024, then surged by 154.93% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $89.5 million for Q2 2025, and $13.6 million during Q1 2025.